Internal Medicine Department. Fundación Instituto de Investigación Sanitaria de Las Islas Baleares, Son Llàtzer University Hospital, Crta Manacor Km 4., 07198, Palma, Spain.
Balearic Research Group in Genetic Cardiopathies, Sudden Death and TTR Amyloidosis. Health Research Institute of the Balearic Islands (IdISBa), Son Llàtzer University Hospital, Palma, Spain.
Orphanet J Rare Dis. 2023 Aug 31;18(1):255. doi: 10.1186/s13023-023-02865-5.
Variant transthyretin amyloidosis (A-ATTRv) is an autosomal dominant disease caused by a range of TTR gene variants which entail great phenotypical heterogeneity and penetrance. In Majorca, the A-ATTRv caused by the V30M gene variant (A-ATTRV30M) is the most common. Since asymptomatic carriers are at risk of developing the disease, estimating age of onset is vital for proper management and follow-up. Thus, the aim of this study was to estimate age-related penetrance in ATTRV30M variant carriers from Majorca.
The disease risk among carriers from ATTRV30M families from Majorca was estimated by Non-parametric survival estimation. Factors potentially involved in the disease expression, namely gender and parent of origin were also analysed.
A total of 48 heterozygous ATTRV30M families (147 affected patients and 123 were asymptomatic carriers) were included in the analysis. Penetrance progressively increased from 6% at 30 years to 75% at 90 years of age. In contrast to other European populations, we observe a similar risk for both males and females, and no difference of risk according to the parent of origin.
In this first study assessing the age-related penetrance of ATTRV30M variant in Majorcan families, no effect of gender or parent of origin was observed. These findings will be helpful for improving management and follow-up of TTR variant carrier individuals.
变异转甲状腺素蛋白淀粉样变(A-ATTRv)是一种常染色体显性遗传病,由一系列 TTR 基因突变引起,具有很大的表型异质性和外显率。在马略卡岛,由 V30M 基因突变引起的 A-ATTRv(A-ATTRV30M)最为常见。由于无症状携带者有患该病的风险,因此估计发病年龄对于适当的管理和随访至关重要。因此,本研究旨在估计马略卡岛 ATTRV30M 变异携带者的年龄相关外显率。
通过非参数生存估计来估计来自马略卡岛 ATTRV30M 家族携带者的疾病风险。还分析了可能涉及疾病表达的因素,即性别和父母来源。
共纳入 48 个 ATTRV30M 杂合子家族(147 名受累患者和 123 名无症状携带者)进行分析。外显率从 30 岁时的 6%逐渐增加到 90 岁时的 75%。与其他欧洲人群不同,我们观察到男性和女性的风险相似,并且与父母来源无关。
在这项评估马略卡家族 ATTRV30M 变异年龄相关外显率的首次研究中,未观察到性别或父母来源的影响。这些发现将有助于改善 TTR 变异携带者个体的管理和随访。